All articles by Phillip Broadwith – Page 21
-
Business
First biosimilar antibody drugs approved in Europe
European commission gives final approval to generic infliximab copies
-
Business
GSK divests Lucozade and Ribena brands
£1.35 billion deal allows GSK to focus on pharma business
-
Business
Otsuka to buy Astex for $886 million
Japanese firm intends to leave Astex’s fragment-based R&D efforts intact
-
Business
J&J buys Aragon’s prostate cancer arm
Hormone cancer specialist spins out other programmes before sale
-
Business
Boehringer to close manufacturing plants and cut jobs
Two US plants and a total of 640 jobs to go by the end of next year
-
Business
AkzoNobel sells building adhesives unit for €260m
Sika will take on two manufacturing sites and 550 employees
-
Business
Antiviral patents released by Roche
Firm will supply cheap drugs and allow generics in developing countries
-
Business
India revokes more pharma patents
Original molecule patent stands, but a new salt form is ‘not innovative’
-
Business
Gas specialist branches out into carbon nanotubes
Linde group launches ink made with long, individual tubes
-
Business
PolyOne to close six sites and shed 250 jobs
Former Spartech manufacturing facilities are ‘redundant’ after takeover in March
-
Business
Monsanto abandons GM crops in Europe
Company will focus on conventional plant breeding in EU and biotech elsewhere
-
Business
GSK under investigation over corruption in China
Police claim executives engaged in bribery and tax-related crimes
-
Business
Chemistry will underpin economic growth, say industry leaders
The UK chemical sector needs to rebuild supply chains and present a unified voice to government
-
Podcast
Imidacloprid
Phillip Broadwith discusses one of the neonicotinoid insecticides believed to be causing problems for bees
-
Business
Biosimilar drugs step up complexity
First generic monoclonal antibodies recommended for approval in Europe
-
Business
Data-sharing partnership for drug discovery
Collaborative project aims to assist medicinal chemistry efforts
-
Business
Ups and downs for erectile dysfunction drugs
First new drug in a decade approved in Europe as Viagra patent expires